The BLZF1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population featuring targeted disruption of the BLZF1 gene in the widely used Jurkat T-cell leukemia line. This knockout model abolishes expression of the basic leucine zipper (bZIP) transcription factor BLZF1, offering a powerful tool for dissecting its transcriptional regulatory functions in a T-lymphocyte context. The polyclonal format minimizes clonal biases and ensures that downstream analyses capture the collective behavior of a heterogeneous knockout pool, enhancing the statistical robustness of comparative studies.
The Jurkat host cell line is a suspension culture derived from the peripheral blood of a 14-year-old male patient with acute T-cell leukemia. These cells harbor constitutively active T-cell receptor (TCR) signaling and express markers characteristic of early thymocytes, making them a canonical model for investigating TCR-mediated signal transduction, apoptosis, and leukemogenesis. Jurkat cells are extensively employed in studies of T-cell activation, cytokine production, and the molecular underpinnings of T-cell acute lymphoblastic leukemia (T-ALL), providing a physiologically relevant platform for functional genomics.
BLZF1 encodes a bZIP transcription factor that integrates signals from several key pathways to regulate genes controlling cell cycle progression and apoptosis. Upstream of BLZF1, TCR engagement activates the ZAP70-LAT-GRB2-RAS-MEK-ERK cascade and the IKK-NF-??B pathway, while cytokines IL-2 and IL-15 provide additional regulatory inputs. BLZF1 modulates expression of c-MYC, Cyclin D1 (CCND1), Bcl-xL (BCL2L1), and p21 (CDKN1A). It interacts with bZIP partners (e.g., C/EBP, ATF), coactivators such as CBP/p300, and chromatin remodeling complexes to coordinate gene expression programs governing T-cell proliferation and survival.
Disruption of BLZF1 in Jurkat T-ALL cells eliminates BLZF1-dependent transcriptional networks, providing a loss-of-function model to study how this factor influences leukemic cell growth. Given BLZF1’s potential dual role as a tumor suppressor or oncogene depending on cellular context, this polyclonal knockout system allows researchers to examine its impact on deregulated cell cycle and apoptosis signaling in a well-characterized leukemia background. The model is particularly valuable for dissecting the crosstalk between TCR, MAPK/ERK, and NF-??B pathways and for exploring how BLZF1 target genes such as c-MYC and BCL2L1 contribute to therapeutic resistance and malignant transformation.
Typical applications of the BLZF1 Knockout Jurkat Polyclonal Cells include transcriptomic profiling by RNA-seq to identify BLZF1-regulated gene networks, flow cytometry-based cell cycle and apoptosis assays, and MTT proliferation assays to assess cytotoxic drug responses. Co-immunoprecipitation and ChIP-qPCR studies can be employed to investigate protein interactions and chromatin occupancy of BLZF1 partners. These cells also serve as a platform for screening compounds that target BLZF1-dependent pathways in T-ALL. For further details or to discuss customized applications, please contact Ascent Research.
